Jones Financial Companies Lllp Sells 12,571 Shares of Amgen Inc. $AMGN

Jones Financial Companies Lllp trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 8.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 141,894 shares of the medical research company’s stock after selling 12,571 shares during the period. Jones Financial Companies Lllp’s holdings in Amgen were worth $50,853,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Dogwood Wealth Management LLC raised its holdings in Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares in the last quarter. Anfield Capital Management LLC grew its stake in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares in the last quarter. Tower View Wealth Management LLC grew its stake in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after buying an additional 63 shares in the last quarter. Manning & Napier Advisors LLC increased its holdings in Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares during the period. Finally, Ares Financial Consulting LLC acquired a new position in shares of Amgen in the 4th quarter valued at approximately $34,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. BMO Capital Markets increased their price target on shares of Amgen from $400.00 to $450.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 6th. Royal Bank Of Canada increased their price objective on shares of Amgen from $370.00 to $400.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group raised their target price on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Finally, Mizuho upped their price target on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $380.43.

Amgen Stock Performance

NASDAQ AMGN opened at $443.84 on Tuesday. The company has a market capitalization of $239.95 billion, a price-to-earnings ratio of 27.58, a PEG ratio of 3.17 and a beta of 0.41. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $445.87. The stock has a fifty day simple moving average of $380.90 and a 200 day simple moving average of $362.81. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the previous year, the business earned $6.02 EPS. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts expect that Amgen Inc. will post 22.92 EPS for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be issued a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s dividend payout ratio is presently 62.65%.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock valued at $2,540,926 in the last three months. Insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.